Glenmark Pharmaceuticals Inc., USA to Launch Potassium Phosphates Injection USP - Expected Annual Sales of $50.7 Million

Glenmark Pharmaceuticals Inc., USA is set to launch Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials in March 2026. The product is bioequivalent and therapeutically equivalent to the reference listed drug of Fresenius Kabi. The market for this product achieved annual sales of approximately $50.7 million as per IQVIA® sales data for the 12-month period ending January 2026.